EU301 / Eutilex - LARVOL DELTA

Eutilex to start Korea’s 1st clinical trial for CAR-T in treating solid cancers (Korea Biomedical Review) - "Eutilex said it would begin clinical trials for a CAR-T treatment to treat solid cancer for the first time in Korea. The company plans to submit an investigational new drug application (IND) for its CAR-T treatment pipeline in the second half of this year and has already secured non-clinical efficacy data. EU307 (GPC3-IL18 CAR-T treatment), the candidate set for IND application, targets GPC3, a substance overexpressed in 70-80 percent of liver cancer patients among solid cancers....'In addition to EU307, Eutilex will also apply for EU301 (MVR CAR-T treatment) targeting HLA-DR and apply a patent for EU309, a treatment targeting brain tumors'..."

New trial • Patent • Brain Cancer • CNS Tumor • Gastrointestinal Cancer • Liver Cancer • Oncology • Solid Tumor

Eutilex’s CAR-T cell therapy wins US patent (Korea Biomedical Review) - "Eutilex said Wednesday that it obtained a patent for the malignancy variant receptor (MVR) CAR-T (chimeric-antigen receptor T) therapy in the United States. The company’s CAR-T cell therapy for MVR targets overexpressed HLA (Human Leukocyte Antigen)-DR in tumors...Eutilex also signed a deal to develop and manufacture clinical agent EU505, which is under development as double-antibody immunotherapy."

Licensing / partnership • Patent • Oncology